A novel JAK-STAT inhibitor, 2-[(3-Carbamoyl-2-thienyl)amino]-2-oxoethyl(2,6-dichlorophenyl)acetate, suppresses helper T cell differentiation in vitro and collagen-induced arthritis in vivo

Mayako Asakawa, Hideyuki Yoshida, Ryota Sakai, Keita Saeki, Masahiro Okada, Mitsuhiro Kanamori, Hitoshi Kotani, Xuetao Wei, Akihiko Yoshimura

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Th17 cells, which have been implicated in autoimmune diseases including rheumatoid arthritis (RA), require the JAK-STAT3 pathway for their differentiation and functions. Recently, JAK inhibitors have been developed as a therapeutic drug for RA. However, the current JAK inhibitors are not optimized to STAT3 compared with other STATs. In this study, we found a new lead compound of a small molecule JAK-STAT inhibitor, 2-[(3-Carbamoyl-2-thienyl)amino]-2-oxoethyl (2,6-dichlorophenyl)acetate, which inhibits STAT3 as efficiently as other STATs. This compound, named JI069, was selected by STAT3 reporter assay in combination with an in silico docking model. JI069 inhibited gp130 signaling by inducing dissociation between gp130 and JAK1. In HEK293T cells and primary T cells, JI069 suppressed STAT3 activation as efficiently as other STATs, including STAT1, STAT5, and STAT6. JI069 effectively suppressed Th1, Th2, and Th17 differentiation while strongly promoted iTreg differentiation. JI069 suppressed symptoms of the collagen-induced arthritis (CIA) model in mice, and inhibited the cytokine production from T cells as well as the STAT3 phosphorylation of synovial cells. These data suggest that JI069 is a new type of JAK inhibitor which has potential for the treatment of immunological disorders.

Original languageEnglish
Pages (from-to)766-773
Number of pages8
JournalBiochemical and Biophysical Research Communications
Volume468
Issue number4
DOIs
Publication statusPublished - 2015 Dec 25

Fingerprint

Experimental Arthritis
T-cells
Helper-Inducer T-Lymphocytes
Cell Differentiation
Rheumatoid Arthritis
Acetates
Collagen
Lead compounds
T-Lymphocytes
Th17 Cells
Phosphorylation
Computer Simulation
Autoimmune Diseases
Assays
Chemical activation
Cytokines
Molecules
Pharmaceutical Preparations
In Vitro Techniques
Therapeutics

Keywords

  • Cytokine signaling
  • Helper T cells
  • JAK1
  • STAT3
  • Th17

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

A novel JAK-STAT inhibitor, 2-[(3-Carbamoyl-2-thienyl)amino]-2-oxoethyl(2,6-dichlorophenyl)acetate, suppresses helper T cell differentiation in vitro and collagen-induced arthritis in vivo. / Asakawa, Mayako; Yoshida, Hideyuki; Sakai, Ryota; Saeki, Keita; Okada, Masahiro; Kanamori, Mitsuhiro; Kotani, Hitoshi; Wei, Xuetao; Yoshimura, Akihiko.

In: Biochemical and Biophysical Research Communications, Vol. 468, No. 4, 25.12.2015, p. 766-773.

Research output: Contribution to journalArticle

Asakawa, Mayako ; Yoshida, Hideyuki ; Sakai, Ryota ; Saeki, Keita ; Okada, Masahiro ; Kanamori, Mitsuhiro ; Kotani, Hitoshi ; Wei, Xuetao ; Yoshimura, Akihiko. / A novel JAK-STAT inhibitor, 2-[(3-Carbamoyl-2-thienyl)amino]-2-oxoethyl(2,6-dichlorophenyl)acetate, suppresses helper T cell differentiation in vitro and collagen-induced arthritis in vivo. In: Biochemical and Biophysical Research Communications. 2015 ; Vol. 468, No. 4. pp. 766-773.
@article{5d105911c39248c49013a32ffe85fdee,
title = "A novel JAK-STAT inhibitor, 2-[(3-Carbamoyl-2-thienyl)amino]-2-oxoethyl(2,6-dichlorophenyl)acetate, suppresses helper T cell differentiation in vitro and collagen-induced arthritis in vivo",
abstract = "Th17 cells, which have been implicated in autoimmune diseases including rheumatoid arthritis (RA), require the JAK-STAT3 pathway for their differentiation and functions. Recently, JAK inhibitors have been developed as a therapeutic drug for RA. However, the current JAK inhibitors are not optimized to STAT3 compared with other STATs. In this study, we found a new lead compound of a small molecule JAK-STAT inhibitor, 2-[(3-Carbamoyl-2-thienyl)amino]-2-oxoethyl (2,6-dichlorophenyl)acetate, which inhibits STAT3 as efficiently as other STATs. This compound, named JI069, was selected by STAT3 reporter assay in combination with an in silico docking model. JI069 inhibited gp130 signaling by inducing dissociation between gp130 and JAK1. In HEK293T cells and primary T cells, JI069 suppressed STAT3 activation as efficiently as other STATs, including STAT1, STAT5, and STAT6. JI069 effectively suppressed Th1, Th2, and Th17 differentiation while strongly promoted iTreg differentiation. JI069 suppressed symptoms of the collagen-induced arthritis (CIA) model in mice, and inhibited the cytokine production from T cells as well as the STAT3 phosphorylation of synovial cells. These data suggest that JI069 is a new type of JAK inhibitor which has potential for the treatment of immunological disorders.",
keywords = "Cytokine signaling, Helper T cells, JAK1, STAT3, Th17",
author = "Mayako Asakawa and Hideyuki Yoshida and Ryota Sakai and Keita Saeki and Masahiro Okada and Mitsuhiro Kanamori and Hitoshi Kotani and Xuetao Wei and Akihiko Yoshimura",
year = "2015",
month = "12",
day = "25",
doi = "10.1016/j.bbrc.2015.11.030",
language = "English",
volume = "468",
pages = "766--773",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - A novel JAK-STAT inhibitor, 2-[(3-Carbamoyl-2-thienyl)amino]-2-oxoethyl(2,6-dichlorophenyl)acetate, suppresses helper T cell differentiation in vitro and collagen-induced arthritis in vivo

AU - Asakawa, Mayako

AU - Yoshida, Hideyuki

AU - Sakai, Ryota

AU - Saeki, Keita

AU - Okada, Masahiro

AU - Kanamori, Mitsuhiro

AU - Kotani, Hitoshi

AU - Wei, Xuetao

AU - Yoshimura, Akihiko

PY - 2015/12/25

Y1 - 2015/12/25

N2 - Th17 cells, which have been implicated in autoimmune diseases including rheumatoid arthritis (RA), require the JAK-STAT3 pathway for their differentiation and functions. Recently, JAK inhibitors have been developed as a therapeutic drug for RA. However, the current JAK inhibitors are not optimized to STAT3 compared with other STATs. In this study, we found a new lead compound of a small molecule JAK-STAT inhibitor, 2-[(3-Carbamoyl-2-thienyl)amino]-2-oxoethyl (2,6-dichlorophenyl)acetate, which inhibits STAT3 as efficiently as other STATs. This compound, named JI069, was selected by STAT3 reporter assay in combination with an in silico docking model. JI069 inhibited gp130 signaling by inducing dissociation between gp130 and JAK1. In HEK293T cells and primary T cells, JI069 suppressed STAT3 activation as efficiently as other STATs, including STAT1, STAT5, and STAT6. JI069 effectively suppressed Th1, Th2, and Th17 differentiation while strongly promoted iTreg differentiation. JI069 suppressed symptoms of the collagen-induced arthritis (CIA) model in mice, and inhibited the cytokine production from T cells as well as the STAT3 phosphorylation of synovial cells. These data suggest that JI069 is a new type of JAK inhibitor which has potential for the treatment of immunological disorders.

AB - Th17 cells, which have been implicated in autoimmune diseases including rheumatoid arthritis (RA), require the JAK-STAT3 pathway for their differentiation and functions. Recently, JAK inhibitors have been developed as a therapeutic drug for RA. However, the current JAK inhibitors are not optimized to STAT3 compared with other STATs. In this study, we found a new lead compound of a small molecule JAK-STAT inhibitor, 2-[(3-Carbamoyl-2-thienyl)amino]-2-oxoethyl (2,6-dichlorophenyl)acetate, which inhibits STAT3 as efficiently as other STATs. This compound, named JI069, was selected by STAT3 reporter assay in combination with an in silico docking model. JI069 inhibited gp130 signaling by inducing dissociation between gp130 and JAK1. In HEK293T cells and primary T cells, JI069 suppressed STAT3 activation as efficiently as other STATs, including STAT1, STAT5, and STAT6. JI069 effectively suppressed Th1, Th2, and Th17 differentiation while strongly promoted iTreg differentiation. JI069 suppressed symptoms of the collagen-induced arthritis (CIA) model in mice, and inhibited the cytokine production from T cells as well as the STAT3 phosphorylation of synovial cells. These data suggest that JI069 is a new type of JAK inhibitor which has potential for the treatment of immunological disorders.

KW - Cytokine signaling

KW - Helper T cells

KW - JAK1

KW - STAT3

KW - Th17

UR - http://www.scopus.com/inward/record.url?scp=84949591178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949591178&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2015.11.030

DO - 10.1016/j.bbrc.2015.11.030

M3 - Article

VL - 468

SP - 766

EP - 773

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 4

ER -